A comparison of echocardiographic and circulating cardiac biomarkers for predicting incident cardiovascular disease.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 27 04 2022
accepted: 07 07 2022
entrez: 25 7 2022
pubmed: 26 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Echocardiographic measures are known predictors of cardiovascular disease (CVD) in the general population. This study compared the predictive value of such measures to that of circulating cardiac biomarkers for a composite cardiovascular disease outcome in an aging population. In this prospective population-based cohort study, echocardiography was performed at baseline together with assessments of traditional CVD risk factors and circulating cardiac biomarkers, NT-proBNP and troponin I, in 1016 individuals all aged 70 years. Assessments were repeated at ages 75 and 80. A composite CVD outcome (myocardial infarction, heart failure or ischemic stroke) was charted over 15 years. All echocardiography variables, except for the E/A ratio, were analyzed on a continuous scale. Over 10 years, left atrial (LA) diameter, left ventricular mass index (LVMI) and high E/A ratio (>1.5) increased, while left ventricular ejection fraction (LVEF) remained unchanged. Using Cox proportional hazard analyses with time-updated variables for echocardiographic measures and traditional risk factors, an enlarged LA diameter and a low LVEF were independently related to incident CVD in 222 participants. The addition of LA diameter and LVEF to traditional risk factors increased the C-statistic by 1.5% (p = 0.008). However, the addition of troponin I and NT-proBNP to traditional risk factors increased the C-statistic by 3.0% (p<0.001). An enlarged LA diameter and a low LVEF improved the prediction of incident CVD compared to traditional risk factors. However, given that troponin I and NT-proBNP improved prediction to a similar extent, the use of simple blood tests to improve clinical cardiovascular disease risk prediction is only further supported by this study.

Sections du résumé

BACKGROUND
Echocardiographic measures are known predictors of cardiovascular disease (CVD) in the general population. This study compared the predictive value of such measures to that of circulating cardiac biomarkers for a composite cardiovascular disease outcome in an aging population.
METHODS
In this prospective population-based cohort study, echocardiography was performed at baseline together with assessments of traditional CVD risk factors and circulating cardiac biomarkers, NT-proBNP and troponin I, in 1016 individuals all aged 70 years. Assessments were repeated at ages 75 and 80. A composite CVD outcome (myocardial infarction, heart failure or ischemic stroke) was charted over 15 years. All echocardiography variables, except for the E/A ratio, were analyzed on a continuous scale.
RESULTS
Over 10 years, left atrial (LA) diameter, left ventricular mass index (LVMI) and high E/A ratio (>1.5) increased, while left ventricular ejection fraction (LVEF) remained unchanged. Using Cox proportional hazard analyses with time-updated variables for echocardiographic measures and traditional risk factors, an enlarged LA diameter and a low LVEF were independently related to incident CVD in 222 participants. The addition of LA diameter and LVEF to traditional risk factors increased the C-statistic by 1.5% (p = 0.008). However, the addition of troponin I and NT-proBNP to traditional risk factors increased the C-statistic by 3.0% (p<0.001).
CONCLUSION
An enlarged LA diameter and a low LVEF improved the prediction of incident CVD compared to traditional risk factors. However, given that troponin I and NT-proBNP improved prediction to a similar extent, the use of simple blood tests to improve clinical cardiovascular disease risk prediction is only further supported by this study.

Identifiants

pubmed: 35877671
doi: 10.1371/journal.pone.0271835
pii: PONE-D-22-12354
pmc: PMC9312363
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
Troponin I 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0271835

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Cardiol. 2015;187:256-63
pubmed: 25838227
Am J Cardiol. 2009 Apr 1;103(7):1032-8
pubmed: 19327437
Eur J Heart Fail. 2005 Aug;7(5):787-91
pubmed: 15916919
Eur Heart J. 2008 Mar;29(6):741-7
pubmed: 18204091
Am J Cardiol. 2001 May 1;87(9):1051-7
pubmed: 11348601
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
J Am Coll Cardiol. 2001 Mar 15;37(4):1042-8
pubmed: 11263606
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2368-75
pubmed: 16141402
J Hypertens. 2019 Feb;37(2):325-330
pubmed: 30113528
Am J Cardiol. 2013 Jan 1;111(1):131-6
pubmed: 23040598
BMJ Open. 2017 Jun 26;7(6):e013431
pubmed: 28652289
Medicine (Baltimore). 2016 Dec;95(52):e5703
pubmed: 28033267
Circulation. 2003 Aug 26;108(8):977-82
pubmed: 12912813
JACC Cardiovasc Imaging. 2012 Feb;5(2):131-40
pubmed: 22340818
Am J Cardiol. 2006 Jan 1;97(1):83-9
pubmed: 16377289
Eur Heart J. 2009 Apr;30(7):773-81
pubmed: 19264749
Lancet Diabetes Endocrinol. 2016 Oct;4(10):840-9
pubmed: 27599814
Circulation. 2001 May 15;103(19):2346-51
pubmed: 11352882
N Engl J Med. 1990 May 31;322(22):1561-6
pubmed: 2139921
Ann Clin Biochem. 2004 Nov;41(Pt 6):459-63
pubmed: 15588434
Int J Cardiol. 2018 Apr 15;257:300-305
pubmed: 29506712
Eur Heart J. 2007 May;28(9):1128-34
pubmed: 17459902
J Am Coll Cardiol. 2013 May 7;61(18):1906-13
pubmed: 23500239
Am J Cardiol. 2005 Sep 15;96(6):832-6
pubmed: 16169372
Am J Cardiol. 2003 Jul 1;92(1):88-90
pubmed: 12842258
Eur J Epidemiol. 2000 Mar;16(3):235-43
pubmed: 10870938
J Am Coll Cardiol. 2008 Dec 16;52(25):2148-55
pubmed: 19095132
N Engl J Med. 1997 May 8;336(19):1350-5
pubmed: 9134875

Auteurs

Lars Lind (L)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Jordan Loader (J)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Inserm U1300 -HP2, Université Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France.

Bertil Lindahl (B)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Kai M Eggers (KM)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Johan Sundström (J)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
The George Institute for Global Health, University of New South Wales, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH